Here the authors describe the discovery of a class of small molecule splicing modifiers which are orally bioavailable, cross the blood-brain barrier, and lower levels of huntingtin in a mouse model of Huntington’s disease (HD).
- Anuradha Bhattacharyya
- Christopher R. Trotta
- Stuart W. Peltz